Opdivo (nivolumab) • Avastin (bevacizumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis (clinicaltrials.gov)

P1/2, N=134, Recruiting, Neonc Technologies, Inc. | Trial completion date: Aug 2026 --> Aug 2027 | Trial primary completion date: Feb 2026 --> Feb 2027

1 month ago

Trial completion date • Trial primary completion date • IO biomarker

PD-L1 (Programmed death ligand 1)

IDH wild-type

Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Yervoy (ipilimumab) • carboplatin • paclitaxel • 5-fluorouracil • Stivarga (regorafenib) • oxaliplatin • irinotecan • leucovorin calcium • Vegzelma (bevacizumab-adcd) • Zaltrap (ziv-aflibercept IV)

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial (clinicaltrials.gov)

P2, N=535, Not yet recruiting, City of Hope Medical Center

1 month ago

New P2 trial • IO biomarker

Avastin (bevacizumab) • Imfinzi (durvalumab) • Imjudo (tremelimumab-actl) • Krazati (adagrasib) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (clinicaltrials.gov)

P3, N=255, Not yet recruiting, National Cancer Institute (NCI) | Initiation date: Dec 2025 --> Mar 2026

1 month ago

Trial initiation date • pMMR

TP53 mutation

Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • paclitaxel • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery (clinicaltrials.gov)

P2, N=169, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Jan 2025

1 month ago

Trial completion • Trial completion date

BRAF (B-raf proto-oncogene)

BRAF mutation • BRAF wild-type

Avastin (bevacizumab) • Yervoy (ipilimumab) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)

Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial (clinicaltrials.gov)

P3, N=129, Not yet recruiting, City of Hope Medical Center

1 month ago

New P3 trial

Avastin (bevacizumab) • irinotecan • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Jelmyto (mitomycin urothelial gel) • fluorouracil topical

2ms

TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors (clinicaltrials.gov)

P1, N=50, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2025 --> Oct 2026

2 months ago

Trial completion date

BRAF (B-raf proto-oncogene)

Avastin (bevacizumab) • sapanisertib (CB-228) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)

3ms

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (clinicaltrials.gov)

P1/2, N=280, Recruiting, Merck Sharp & Dohme LLC | N=78 --> 280

3 months ago

Enrollment change

Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • paclitaxel • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • raludotatug deruxtecan (DS-6000)

4ms

NCI-2018-01503: Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)

P2, N=96, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026

4 months ago

Trial completion date • Trial primary completion date • Platinum resistant

MSLN (Mesothelin)

Avastin (bevacizumab) • paclitaxel • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • anetumab ravtansine (BAY 94-9343)

4ms

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers (clinicaltrials.gov)

P1, N=90, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Jun 2029 --> May 2030 | Trial primary completion date: Jul 2028 --> May 2030

4 months ago

Trial completion date • Trial primary completion date

Avastin (bevacizumab) • Libtayo (cemiplimab-rwlc) • Vegzelma (bevacizumab-adcd)

4ms

CALGB 40603: Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery (clinicaltrials.gov)

P2, N=454, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Feb 2026 --> Sep 2025

4 months ago

Trial completion • Trial completion date

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)

HER-2 negative

Avastin (bevacizumab) • carboplatin • paclitaxel • doxorubicin hydrochloride • cyclophosphamide • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn)

4ms

Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer (clinicaltrials.gov)

P1/2, N=85, Recruiting, Mayo Clinic | N=54 --> 85

4 months ago

Enrollment change • Checkpoint inhibition

Avastin (bevacizumab) • Tecentriq (atezolizumab) • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • tiragolumab (RG6058)